IOncology

On May 16, 2024, the European Society for Medical Oncology Breast Cancer Annual Meeting (ESMO BC) reported updated results from the CAPItello-291 study (183MO). The data showed that the AKT inhibitor capivasertib combined with fulvestrant provided benefits in second-line treatment without affecting the benefits of subsequent treatments. This further solidified capivasertib's role in the post-CDK4/6 inhibitor (CDK4/6i) era, leading the way in precision therapy for HR+ breast cancer. Oncology Frontier interviewed Professor Yiding Chen from The Second Affiliated Hospital of Zhejiang University School of Medicine to analyze the progress of the CAPItello-291 study and discuss superior treatment options in the post-CDK4/6i era from mechanisms to clinical applications.

The highly anticipated 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has officially begun. As a premier global academic conference in oncology, ASCO attracts professionals from around the world to share and discuss the latest clinical oncology research findings and treatment advancements. At this year's conference, the research led by Professor Yu Chen from Fujian Cancer Hospital, titled "First-In-Class PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 for Advanced Melanoma," has been selected for poster presentation. This study marks the global debut of the independently developed IBI363 by Innovent Biologics for melanoma treatment, highlighting significant progress in evaluating its safety, tolerable dosage, and efficacy, especially in acral and mucosal melanoma subtypes specific to China.

The 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be held from May 31 to June 4 in Chicago, Eastern Time. Two studies led by Professor Jiayu Wang from Academician Binghe Xu's team at the Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS) have been selected for poster presentation at the ASCO Annual Meeting. This article introduces these studies (Abstract Numbers: 1058, 3117).

In recent years, significant progress has been made in the treatment of renal cell carcinoma (RCC). However, selecting the appropriate treatment strategy remains a critical challenge. Traditional tumor markers have limited predictive value in RCC, making the search for new and reliable biomarkers to guide treatment decisions a hot topic in RCC research. As one of the major oncology events of 2024, the ASCO Annual Meeting is set to take place soon. Oncology Outlook has invited Professor Guohai Shi from Fudan University Cancer Hospital to share the major research findings on kidney cancer biomarkers that will be presented at the conference.

In recent years, significant progress has been made in the treatment of renal cell carcinoma (RCC). However, selecting the appropriate treatment strategy remains a critical challenge. Traditional tumor markers have limited predictive value in RCC, making the search for new and reliable biomarkers to guide treatment decisions a hot topic in RCC research. As one of the major oncology events of 2024, the ASCO Annual Meeting is set to take place soon. Oncology Outlook has invited Professor Guohai Shi from Fudan University Cancer Hospital to share the major research findings on kidney cancer biomarkers that will be presented at the conference

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will take place in Chicago from May 31 to June 4. Led by Professor Nanlin Li from Xijing Hospital of the Air Force Medical University, a single-center, single-arm phase II clinical study focused on the efficacy and safety of the HER2-targeting antibody-drug conjugate (ADC) RC48 in the neoadjuvant treatment of HER2-positive breast cancer has disclosed its data. The study shows that although RC48 achieved lower pathological complete response rates (pCR) compared to traditional chemotherapy combined with targeted therapy, it effectively reduced tumor size rapidly, achieved moderate to significant remission, and had high safety with minimal toxicity. These findings provide a new option for neoadjuvant treatment of HER2-positive breast cancer and may expand the indications for domestically developed ADC drugs. This article reports the relevant data.

Several studies presented at the 2024 ESMO Breast Cancer (ESMO BC) conference demonstrated the potential efficacy of new CDK4 selective inhibitors and the lasting benefits of pan-AKT inhibitors. The latest results from the first human study of a new CDK4 selective inhibitor were presented at the 2024 ESMO BC conference (May 15-17, Berlin). This study showed promising efficacy and safety in heavily pretreated hormone receptor-positive (HR+)/HER2- metastatic breast cancer (mBC) patients. Among 25 patients who progressed on prior CDK4/6 inhibitor therapy combined with endocrine therapy (ET) and had measurable disease, the first-in-class next-generation CDK4 selective inhibitor PF-07220060 combined with ET (letrozole or fulvestrant) resulted in 1 complete response (CR) and 7 partial responses (PR) (Abstract 184MO). The clinical benefit response rate for the total population was 64.0%, with a median progression-free survival (PFS) of 8.1 months. Responses were independent of ESR1 or PI3K pathway mutations

Primary liver cancer is one of the leading causes of cancer death worldwide, and its treatment strategies have seen significant advancements in recent years. At the recent 2024 Chinese Society of Clinical Oncology (CSCO) Guideline Conference, Professor Xinlei Gong from Jinling Hospital, Nanjing University School of Medicine, delivered an outstanding lecture on the topic of "Updates in Systemic Therapy for Hepatocellular Carcinoma." "Oncology Watch" has compiled the main points of his lecture to provide readers with a deeper understanding of the latest advancements in systemic therapy for liver cancer.

With the success of antibody-drug conjugates (ADCs) in treating HER2-low breast cancer patients, this patient group is receiving increased attention. The latest 2024 CSCO BC guidelines were released on April 12 in Beijing, featuring the first recommendations for treating HER2-low patients. "Oncology Frontier" invited Professor Shusen Wang from Sun Yat-sen University Cancer Center to discuss the current treatment landscape for HER2-low patients and the recommendations in the 2024 CSCO BC guidelines.

At the 2024 ESMO BC conference, Professor Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, presented a report titled "From Phase III Clinical Trials to Real-World Data: Bridging the Gap Between Clinical Trials and Clinical Practice." This report delved into the treatment advances for HER2-positive breast cancer, the differences between clinical trials and real-world data, and how to better guide clinical practice. "Oncology Frontier" invited Professor Liu to share insights on his report and the disparities between clinical trials and clinical practice.